Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus SEFFIN.
CEFEPIME HYDROCHLORIDE vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic